ARCA biopharma, Inc. Overview
Pro stress-test →ARCA biopharma is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF).
Strategic Profile
Pro stress-test →ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. ARCA has identified genetic variations in cardiac receptors that it believes may predict individual patient response to Gencaro, giving Gencaro the potential to be the first genetically-targeted prevention treatment for AF.
Competitive Landscape
Pro stress-test →ARCA competes within the cardiovascular disease therapeutics and precision medicine segments. Direct competitors include other precision medicine and genetically-targeted therapy developers focused on cardiac conditions, as well as larger pharmaceutical companies with cardiovascular portfolios. As a clinical-stage company without FDA approvals, ARCA faces significant competitive pressure from established players with approved therapies and greater financial resources.
Industry Context
ARCA biopharma, Inc. operates in Cardiovascular precision medicine therapeutics.
Key facts
Founded: 1992 · Headquarters: Westminster, Colorado, US · Employees: 25 · Revenue: $4 million · Market cap: N/A